Montoliu-Gaya, Laia http://orcid.org/0000-0001-7684-6318
Benedet, Andréa L.
Tissot, Cécile http://orcid.org/0000-0003-2711-3833
Vrillon, Agathe http://orcid.org/0000-0002-0761-7885
Ashton, Nicholas J.
Brum, Wagner S. http://orcid.org/0000-0002-9777-0559
Lantero-Rodriguez, Juan http://orcid.org/0000-0002-7426-678X
Stevenson, Jenna
Nilsson, Johanna http://orcid.org/0000-0002-2856-6060
Sauer, Mathias
Rahmouni, Nesrine
Brinkmalm, Gunnar http://orcid.org/0000-0001-6958-2393
Lussier, Firoza Z. http://orcid.org/0000-0002-6877-4825
Pascoal, Tharick A. http://orcid.org/0000-0001-9057-8014
Skoog, Ingmar
Kern, Silke
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Paquet, Claire
Gobom, Johan
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Article History
Received: 27 November 2022
Accepted: 22 March 2023
First Online: 27 April 2023
Competing interests
: H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside the submitted work). K.B. has served as a consultant, on advisory boards or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Eli Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, outside the work presented in this paper. P.R.N. participated on advisory boards for Roche, Novo Nordisk and Cerveau (outside the submitted work). The remaining authors declare no competing interests.